257 related articles for article (PubMed ID: 32379931)
21. Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A.
Josset L; Leuci A; Janbain M; De-Wreede A; Desage S; Lienhart A; Bin V; Lebert D; Delavenne X; Dargaud Y
J Thromb Haemost; 2024 Jul; 22(7):1857-1866. PubMed ID: 38583717
[TBL] [Abstract][Full Text] [Related]
22. Elevated factor VIII enhances thrombin generation in the presence of factor VIII-deficiency, factor XI-deficiency or fondaparinux.
Szlam F; Sreeram G; Solomon C; Levy JH; Molinaro RJ; Tanaka KA
Thromb Res; 2011 Feb; 127(2):135-40. PubMed ID: 21144556
[TBL] [Abstract][Full Text] [Related]
23. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents.
Hartmann R; Feenstra T; Valentino L; Dockal M; Scheiflinger F
J Thromb Haemost; 2018 Jun; ():. PubMed ID: 29888855
[TBL] [Abstract][Full Text] [Related]
24. Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor.
Nakajima Y; Tonegawa H; Noguchi-Sasaki M; Nogami K
Int J Hematol; 2021 Jun; 113(6):789-796. PubMed ID: 33635530
[TBL] [Abstract][Full Text] [Related]
25. In vitro effects of emicizumab on activated clotting time in blood samples from cardiac surgical patients.
Tanaka KA; Henderson R; Thangaraju K; Morita Y; Mazzeffi MA; Strauss E; Katneni U; Buehler PW
Haemophilia; 2022 Jan; 28(1):183-190. PubMed ID: 34735039
[TBL] [Abstract][Full Text] [Related]
26. Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab.
Atsou S; Schellenberg C; Lagrange J; Lacolley P; Lenting PJ; Denis CV; Christophe OD; Regnault V
J Thromb Haemost; 2024 Jan; 22(1):112-125. PubMed ID: 37776978
[TBL] [Abstract][Full Text] [Related]
27. Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays.
Kizilocak H; Marquez-Casas E; Malvar J; Carmona R; Young G
Haemophilia; 2021 Sep; 27(5):730-735. PubMed ID: 34115433
[TBL] [Abstract][Full Text] [Related]
28. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.
Gelbenegger G; Schoergenhofer C; Knoebl P; Jilma B
Thromb Haemost; 2020 Oct; 120(10):1357-1370. PubMed ID: 32717759
[TBL] [Abstract][Full Text] [Related]
29. FVIII/VWF complex displays a greater pro-haemostatic activity than FVIII preparations devoid of VWF: Study in plasma and cell-based models.
Ammollo CT; Semeraro F; Vitulli A; Dirienzo L; Mezzasoma AM; Semeraro N; Gresele P; Colucci M
Haemophilia; 2020 Jul; 26(4):e151-e160. PubMed ID: 32325538
[TBL] [Abstract][Full Text] [Related]
30. In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab.
Yamaguchi T; Shinozawa K; Nagatoishi S; Mitsuhashi A; Bingo M; Inaba H; Amano K; Tsumoto K; Kinai E
Thromb Res; 2023 Feb; 222():131-139. PubMed ID: 36657269
[TBL] [Abstract][Full Text] [Related]
31. Coagulation factor VIII regulates von Willebrand factor homeostasis invivo.
Cao W; Trask AR; Bignotti AI; George LA; Doshi BS; Sabatino DE; Yada N; Zheng L; Camire RM; Zheng XL
J Thromb Haemost; 2023 Dec; 21(12):3477-3489. PubMed ID: 37726033
[TBL] [Abstract][Full Text] [Related]
32. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
Mannucci PM; Shi Q; Bonanad S; Klamroth R
Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
[TBL] [Abstract][Full Text] [Related]
33. A hemophilia A mouse model for the in vivo assessment of emicizumab function.
Ferrière S; Peyron I; Christophe OD; Kawecki C; Casari C; Muczynski V; Nathwani A; Kauskot A; Lenting PJ; Denis CV
Blood; 2020 Aug; 136(6):740-748. PubMed ID: 32369559
[TBL] [Abstract][Full Text] [Related]
34. Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab.
Kizilocak H; Marquez-Casas E; Malvar J; Young G
Haemophilia; 2023 Jan; 29(1):100-105. PubMed ID: 36287631
[TBL] [Abstract][Full Text] [Related]
35. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
36. An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A.
Takeyama M; Nogami K; Matsumoto T; Noguchi-Sasaki M; Kitazawa T; Shima M
J Thromb Haemost; 2020 Apr; 18(4):825-833. PubMed ID: 31984625
[TBL] [Abstract][Full Text] [Related]
37. The effect of emicizumab and bypassing agents in patients with hemophilia - An in vitro study.
Schultz NH; Glosli H; Bjørnsen S; Holme PA
Res Pract Thromb Haemost; 2021 Jul; 5(5):e12561. PubMed ID: 34263107
[TBL] [Abstract][Full Text] [Related]
38. VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice.
Berntorp E
Haemophilia; 2007 Dec; 13 Suppl 5():69-72. PubMed ID: 18078401
[TBL] [Abstract][Full Text] [Related]
39. Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions.
Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
Thromb Haemost; 2021 Mar; 121(3):279-286. PubMed ID: 32906155
[TBL] [Abstract][Full Text] [Related]
40. In Vitro Comparison of Recombinant and Plasma-Derived von Willebrand Factor Concentrate for Treatment of Acquired von Willebrand Syndrome in Adult Extracorporeal Membrane Oxygenation Patients.
Mazzeffi M; Henderson R; Krause E; Rabin J; Madathil R; Chow J; Grazioli A; Meyer M; Wu Z; Tanaka K
Anesth Analg; 2022 Feb; 134(2):312-321. PubMed ID: 34903705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
